23andMe vs. Whole-Genome Sequencing for BRCA (2026)

01 / 08

Does 23andMe test for BRCA?

Yes. 23andMe's BRCA1/BRCA2 (Selected Variants) report is the first and only FDA-authorized direct-to-consumer BRCA report. It checks 44 variants—not only the original three.

The FDA originally authorized a three-variant report in 2018. In 2023, a clearance under a Predetermined Change Control Plan expanded the report by 41 variants, bringing the current total to 44. ^[1,2,3]

If family history or a known familial variant is driving the decision, first review who should get a clinically indicated BRCA test.

02 / 08

Which variants does the report cover?

The original report checked three founder variants common among people of Ashkenazi Jewish descent. The expansion added 41 variants selected to improve coverage across more populations.

BRCA1

185delAG / c.68_69delAG and 5382insC / c.5266dupC

BRCA2

6174delT / c.5946delT

Those three variants occur in about 1 in 40 people of Ashkenazi Jewish descent. That frequency does not mean ancestry alone determines who carries a pathogenic BRCA variant, and founder testing can miss other clinically important variants. ^[2,6]

How many BRCA variants are known?

Published sources use different totals because they may count different classifications, databases, or reporting dates. The source brief identifies 4,000+ from 23andMe, 3,500+ from genetic counselor Rachel Brandt via Breastcancer.org, and 5,400+ from FORCE. These are not interchangeable denominators, so we do not collapse them into one falsely precise total. ^[2,3,5]

03 / 08

Coverage differs by ancestry

A fixed 44-variant list captures different shares of known pathogenic variants in different populations. The same negative result therefore does not carry the same residual uncertainty for everyone.

23andMe-stated estimated detection rates for its selected BRCA variants by ancestry.
Population	Estimated detection rate	How to interpret it
Ashkenazi Jewish descent	More than 90%	Highest stated coverage, largely reflecting founder variants.
Black, European, Hispanic/Latino	About 30–40%	Most pathogenic variants may remain outside the list.
East Asian	About 5–25%	The stated range is broad and residual uncertainty is substantial.
South Asian	Up to about 35%	“Up to” is not a guarantee for any individual.

These are 23andMe's stated estimates, not individual probabilities. Population labels are broad, ancestry can be mixed, and a person's clinical testing need depends on history as well as ancestry. ^[2]

04 / 08

What does a result mean—and not mean?

Variant detected

Treat it as a finding to confirm

The selected variant is associated with increased risk for certain cancers. Confirm it with a clinical genetic test before any screening, surgical, reproductive, or treatment decision.

No variant detected

Do not read it as “no BRCA risk”

It means none of the 44 selected variants was found. It does not assess thousands of other reported BRCA variants or describe overall cancer risk.

The FDA-required framing is important: confirmatory testing is required before medical decisions; the report is not a substitute for visits with a healthcare professional; and it does not describe a person's overall cancer risk. Genetic counseling is not included with the consumer report. ^[1,2]

05 / 08

23andMe, a clinical panel, or WGS?

These products answer different questions. Compare scope, validation, counseling, and follow-up—not only how much DNA is collected.

A selected-variant check

Understand the narrow scope

The consumer report checks 44 named variants. A negative result cannot exclude other BRCA1/2 variants or inherited risk.

A focused clinical question

Start with genetics guidance

A known family variant or a strong personal or family history may point to targeted testing or a clinical hereditary cancer panel.

A broader inherited-health view

Consider genome-wide scope

WGS extends beyond BRCA, but breadth alone does not establish BRCA-specific accuracy or make the result definitive.

Three-way comparison of at-home selected-variant testing, clinical hereditary cancer panels, and whole-genome sequencing.
Feature	23andMe BRCA report	Clinical hereditary cancer panel	HLI whole-genome sequencing
Listed cost	$199 in the source brief; verify current price	May be $0 out of pocket when criteria and coverage apply; otherwise varies	$599
BRCA scope	Fixed list of 44 selected variants	Clinically focused BRCA1/2 analysis; genes and validated variant classes vary by lab	Cancer assessment states it covers BRCA1/2; specific variants and validated variant classes are not published
Beyond BRCA	Other consumer health reports vary by product	Selected hereditary cancer genes	Genome-wide data plus cancer, cardiovascular, pharmacogenomic, and other findings
Regulatory / validation context	FDA-authorized for specified selected variants; original submission reported >99% concordance to Sanger sequencing	Clinical laboratory methods, confirmation, and performance vary; ask the lab	Not presented as FDA-authorized for cancer-risk reporting; comparative BRCA accuracy and orthogonal confirmation are not published
Counseling	Not included	Often ordered after pre-test counseling, with clinical follow-up	Not a replacement for a genetic counselor or clinical confirmation
Best fit	Narrow consumer screening for selected variants	A focused clinical hereditary-cancer question	A broader inherited-health view from one genome dataset

Prices, coverage, report scope, and laboratory practices change. Confirm current details before ordering. For a broader discussion—not a dedicated side-by-side price quote—review BRCA testing costs, insurance, and privacy.

06 / 08

Why WGS is more comprehensive—and where it is not

Whole-genome sequencing offers a more comprehensive product scope: it collects data across the genome and can support findings across cancer, cardiovascular health, pharmacogenomics, and more in one purchase.

The broader choice

HLI's $599 service uses approximately 30× whole-genome sequencing and includes a cancer risk assessment stated to cover BRCA1 and BRCA2 among other genes.

That genome-wide foundation is categorically broader than a fixed 44-variant list. It does not establish that HLI's BRCA analysis is more accurate, more thoroughly validated, or guaranteed to find every clinically relevant BRCA variant.

See what the $599 genome service includes

Genome breadth and BRCA-specific analytic validation are different properties.

23andMe publishes FDA-audited performance for the selected variants it reports. HLI has not published equivalent head-to-head data, which BRCA variant classes its $599 report validates, or whether findings are checked with an orthogonal method before return. A positive finding from either pathway should be clinically confirmed; a negative result from either should not erase risk indicated by personal or family history.

07 / 08

Frequently asked questions

Q1Does 23andMe test for BRCA?

Yes. Its FDA-authorized BRCA1/BRCA2 (Selected Variants) report checks 44 specific variants. That is broader than the three founder variants in its original 2018 authorization, but it is not comprehensive analysis of every clinically important BRCA1 or BRCA2 variant. ^[1,2]

Q2Is 23andMe's BRCA test FDA-approved?

Use “FDA-authorized,” not “FDA-approved.” The report was authorized through the FDA De Novo pathway as a Class II device. That authorization applies to the selected variants and intended use described by the FDA; it does not make the report comprehensive BRCA testing. ^[1]

Q3Can a negative 23andMe result rule out BRCA risk?

No. A negative result means none of the 44 selected variants was detected. It does not rule out other BRCA1/2 variants, variants in other cancer genes, or risk suggested by personal and family history. Clinical testing may still be appropriate. ^[2,6]

Q4Is whole-genome sequencing more accurate than 23andMe for BRCA?

That has not been established. WGS is broader across the genome and categories of findings. HLI has not published head-to-head BRCA accuracy data, its validated BRCA variant classes, or whether reportable findings are orthogonally confirmed. Breadth is not BRCA-specific analytic validation. ^[1,2]

08 / 08

Sources and review notes

Regulatory and product facts were checked against the source brief on September 28, 2026. The 44-variant count, pricing, service scope, and regulatory status should be rechecked at least every six months. Medical review remains pending for this preview.